Wainua (eplontersen) — Medica
polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR)
Initial criteria
- age ≥ 18 years
- has a transthyretin (TTR) pathogenic variant confirmed by genetic testing
- has symptomatic polyneuropathy
- does not have a history of liver transplantation
- prescribed by or in consultation with a neurologist, geneticist, or physician who specializes in treatment of amyloidosis
- not used in combination with other medications indicated for polyneuropathy of hereditary transthyretin-mediated amyloidosis or transthyretin-mediated amyloidosis-cardiomyopathy (e.g., Amvuttra, Attruby, Onpattro, Tegsedi, tafamidis products)
Approval duration
1 year